Business
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst
April 8, 2026
Benzinga
Scroll
Needham initiates MapLight with Buy, citing ML-007C-MA potential in schizophrenia and AD psychosis, with key readouts expected through 2027. Importance Rank: 1 read more
Benzinga
Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.
United States of America
Bias: center